A citation-based method for searching scientific literature

Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L Bajor, Patricia Cruz, J Thaddeus Beck, Srimoyee Ghosh, Christine Dabrowski, Grace Antony, Tao Duan, Jennifer Veneris, Eleftherios Zografos, Janakiraman Subramanian. Clin Lung Cancer 2022
Times Cited: 2







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Lawrence Kasherman, Soha Ahrari, Stephanie Lheureux. Future Oncol 2021
13
100

An Integrated Analysis of Dostarlimab Immunogenicity.
Sharon Lu, Ronald R Bowsher, Amanda Clancy, Amy Rosen, Mingxuan Zhang, Ying Yang, Kathleen Koeck, Minggeng Gao, Elizabeth Potocka, Wei Guo,[...]. AAPS J 2021
4
100

Dostarlimab: First Approval.
Anthony Markham. Drugs 2021
27
100

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O'Malley, Vanessa Samouelian, Valentina Boni,[...]. J Immunother Cancer 2022
27
100

A review of cancer immunotherapy: from the past, to the present, to the future.
K Esfahani, L Roudaia, N Buhlaiga, S V Del Rincon, N Papneja, W H Miller. Curr Oncol 2020
241
100


Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Sima Singh, Arshid Numan, Nikhil Agrawal, Murtaza M Tambuwala, Vijender Singh, Prashant Kesharwani. Int Immunopharmacol 2020
16
50

Management of locally advanced primary and recurrent rectal cancer.
Johannes H W de Wilt, Maarten Vermaas, Floris T J Ferenschild, Cornelis Verhoef. Clin Colon Rectal Surg 2007
28
50

Cancer statistics, 2022.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2022
50

Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Zahid Hussain, Muhammad Abdur Rahim, Nasrullah Jan, Hassan Shah, Mutasem Rawas-Qalaji, Shahzeb Khan, Mohammad Sohail, Hnin Ei Thu, Nor Amlizan Ramli, Rai Muhammad Sarfraz,[...]. J Control Release 2021
25
50


Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood-brain barrier.
Mohammed As Abourehab, Osama Aa Ahmed, Gehan F Balata, Waleed H Almalki. Int J Nanomedicine 2018
28
50

Monoclonal antibodies in cancer immunotherapy.
Ilgin Kimiz-Gebologlu, Sultan Gulce-Iz, Cigir Biray-Avci. Mol Biol Rep 2018
79
50

A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo. Nat Rev Immunol 2020
50

Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases.
Niloufar Rahiman, Yuliya V Markina, Prashant Kesharwani, Thomas P Johnston, Amirhossein Sahebkar. J Control Release 2022
3
50

Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Soumya Swaminathan, Chandrasekaran Padmapriyadarsini, Perumal Venkatesan, Gopalan Narendran, Santhanakrishnan Ramesh Kumar, Sheik Iliayas, Pradeep A Menon, Sriram Selvaraju, Navaneetha P Pooranagangadevi, Perumal K Bhavani,[...]. Clin Infect Dis 2011
51
50

Computational Identification of Druggable Bioactive Compounds from Catharanthus roseus and Avicennia marina against Colorectal Cancer by Targeting Thymidylate Synthase.
Md Rashedul Islam, Md Abdul Awal, Ahmed Khames, Mohammad A S Abourehab, Abdus Samad, Walid M I Hassan, Rahat Alam, Osman I Osman, Suza Mohammad Nur, Mohammad Habibur Rahman Molla,[...]. Molecules 2022
5
50

The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Sima Singh, Arshid Numan, Balaji Maddiboyina, Saahil Arora, Yassine Riadi, Shadab Md, Nabil A Alhakamy, Prashant Kesharwani. Drug Discov Today 2021
23
50

Advances in cancer immunotherapy 2019 - latest trends.
Stephan Kruger, Matthias Ilmer, Sebastian Kobold, Bruno L Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W Renz, Jan G D'Haese, Hans Schloesser,[...]. J Exp Clin Cancer Res 2019
265
50

Monoclonal Antibodies in Cancer Therapy.
David Zahavi, Louis Weiner. Antibodies (Basel) 2020
144
50

Immune checkpoint inhibitors: a promising anticancer therapy.
Sima Singh, Daniel Hassan, Hibah M Aldawsari, Nagashekhara Molugulu, Rahul Shukla, Prashant Kesharwani. Drug Discov Today 2020
53
50

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Ana Oaknin, Anna V Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim,[...]. JAMA Oncol 2020
102
50

Identification and characterization of a novel antimicrobial peptide compound produced by Bacillus megaterium strain isolated from oral microflora.
Abdullah S A Al-Thubiani, Yahia A Maher, Adel Fathi, Mohammed A S Abourehab, Mohammed Alarjah, Mohd S A Khan, Saleh B Al-Ghamdi. Saudi Pharm J 2018
10
50


Bilosomes in the context of oral immunization: development, challenges and opportunities.
Anshuman Shukla, Vijay Mishra, Prashant Kesharwani. Drug Discov Today 2016
44
50

Immune checkpoint inhibitors win the 2018 Nobel Prize.
Pei-Wei Huang, John Wen-Cheng Chang. Biomed J 2019
33
50

Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.
Ravi Bandaru, Smruti Rekha Rout, Omkar S Kamble, Sangram K Samal, Bapi Gorain, Amirhossein Sahebkar, Farhan J Ahmed, Prashant Kesharwani, Rambabu Dandela. Process Biochem 2022
1
100

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Andrea Cercek, Melissa Lumish, Jenna Sinopoli, Jill Weiss, Jinru Shia, Michelle Lamendola-Essel, Imane H El Dika, Neil Segal, Marina Shcherba, Ryan Sugarman,[...]. N Engl J Med 2022
99
50

Dostarlimab for the treatment of advanced endometrial cancer.
Andres Redondo, Alejandro Gallego, Marta Mendiola. Expert Rev Clin Pharmacol 2022
5
50


PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Tim Wartewig, Zsuzsanna Kurgyis, Selina Keppler, Konstanze Pechloff, Erik Hameister, Rupert Öllinger, Roman Maresch, Thorsten Buch, Katja Steiger, Christof Winter,[...]. Nature 2017
150
50

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
Keisuke Okudaira, Ryota Hokari, Yoshikazu Tsuzuki, Yoshikiyo Okada, Shunsuke Komoto, Chikako Watanabe, Chie Kurihara, Atsushi Kawaguchi, Shigeaki Nagao, Miyuki Azuma,[...]. Int J Oncol 2009
96
50

Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival.
Yohei Masugi, Tokiya Abe, Akihisa Ueno, Yoko Fujii-Nishimura, Hidenori Ojima, Yutaka Endo, Yusuke Fujita, Minoru Kitago, Masahiro Shinoda, Yuko Kitagawa,[...]. Mod Pathol 2019
46
50

The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.
Benjamin G Neel, Haihua Gu, Lily Pao. Trends Biochem Sci 2003
891
50

PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
Nikolaos Patsoukis, Lequn Li, Duygu Sari, Victoria Petkova, Vassiliki A Boussiotis. Mol Cell Biol 2013
121
50

Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison. Science 1996
50

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
Rebecca Kristeleit, Cara Mathews, Andres Redondo, Susan Boklage, Jennifer Hanlon, Ellie Im, Jubilee Brown. Int J Gynecol Cancer 2022
1
100

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel,[...]. Lancet Oncol 2016
441
50

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Amita Patnaik, Glen J Weiss, Drew W Rasco, Lisa Blaydorn, Amy Mirabella, Murali Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern,[...]. Cancer Chemother Pharmacol 2022
2
50

MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma.
Rajesh Pradhan, Gautam Singhvi, Sunil Kumar Dubey, Gaurav Gupta, Kamal Dua. Future Med Chem 2019
25
50

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
Mei Ji, Yan Liu, Qing Li, Xiao-Dong Li, Wei-Qing Zhao, Hanze Zhang, Xiaofei Zhang, Jing-Ting Jiang, Chang-Ping Wu. J Transl Med 2015
59
50

Dostarlimab: A Review.
Bárbara Costa, Nuno Vale. Biomolecules 2022
5
50

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
50

The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
Toshifumi Doi, Takeshi Ishikawa, Tetsuya Okayama, Kaname Oka, Katsura Mizushima, Tomoyo Yasuda, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama,[...]. Oncol Rep 2017
80
50


PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
50

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Jun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott Rodig, Jingjing Li, Xinqi Wu, Lisa H Butterfield,[...]. Cancer Immunol Res 2017
210
50

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
50

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
Shahrzad Jalali, Tammy Price-Troska, Cole Bothun, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J Novak, Haidong Dong, Stephen M Ansell. Blood Cancer J 2019
31
50

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.